Société Générale — M&A Activity 2021

Jun 2, 2021

National Storage Mechanism | Additional information

RNS Number : 5496A

Societe Generale SA

02 June 2021

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1)	Société Générale S.A.
Company dealt in	UDG Healthcare plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	€0.05 ordinary shares
Date of dealing	01/06/2021

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
Number	(%)	Number	(%)
(1) Relevant securities	4,069,272	1.62	4,853	0.00
(2) Derivatives (other than options)	0	0.00	0	0.00
(3) Options and agreements to purchase/sell	0	0.00	0	0.00
Total	*4,129,272	*1.64	4,853	0.00

* Include the holding of 60,000 shares on borrow products

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit GBP (Note 5)
Purchase	150	10.65
Purchase	465	10.65
Purchase	3	10.65
Purchase	129	10.63
Purchase	55	10.63
Purchase	113	10.63
Purchase	125	10.63
Purchase	615	10.63
Purchase	696	10.62
Purchase	200	10.62
Purchase	834	10.57
Purchase	1,151	10.6
Purchase	1,153	10.6
Purchase	58	10.57
Purchase	687	10.6
Purchase	589	10.66
Purchase	601	10.58
Purchase	293	10.58
Purchase	761	10.64
Purchase	407	10.61
Purchase	407	10.61
Purchase	704	10.58
Purchase	1,197	10.59
Purchase	1,194	10.57
Purchase	573	10.65
Purchase	466,000	10.57
Purchase	194,541	10.58
Purchase	5,926	10.58
Purchase	1	10.57
Purchase	1	10.57
Purchase	756	10.66
Purchase	330	10.56
Purchase	153	10.56
Purchase	176	10.56
Purchase	319	10.57
Purchase	196	10.57
Purchase	148	10.66
Purchase	316	10.65
Purchase	324	10.57
Purchase	312	10.56
Purchase	344	10.57
Purchase	347	10.66
Purchase	315	10.56
Purchase	501	10.65
Purchase	148	10.66
Purchase	195	10.56
Purchase	343	10.56
Purchase	305	10.57
Purchase	171	10.57
Purchase	141	10.57
Purchase	268	10.57
Purchase	60	10.57
Purchase	327	10.57
Purchase	330	10.57
Purchase	305	10.66
Purchase	333	10.56
Purchase	146	10.56
Purchase	162	10.56
Purchase	251	10.57
Purchase	105	10.57
Purchase	310	10.56
Purchase	324	10.56
Purchase	318	10.56
Purchase	323	10.56
Purchase	158	10.57
Purchase	143	10.57
Purchase	321	10.57
Purchase	185	10.65
Purchase	353	10.57
Purchase	149	10.66
Purchase	314	10.57
Purchase	5	10.57
Purchase	301	10.57
Purchase	310	10.57
Purchase	304	10.57
Purchase	292	10.65
Purchase	212	10.57
Purchase	194	10.57
Purchase	309	10.57
Purchase	149	10.66
Purchase	246	10.57
Purchase	95	10.57
Purchase	312	10.57
Purchase	264	10.57
Purchase	96	10.57
Purchase	301	10.57
Purchase	5	10.57
Purchase	313	10.57
Purchase	305	10.65
Purchase	320	10.57
Purchase	328	10.57
Purchase	324	10.65
Purchase	311	10.57
Purchase	312	10.56
Purchase	188	10.56
Purchase	333	10.56
Purchase	307	10.57
Purchase	312	10.56
Purchase	326	10.55
Purchase	336	10.55
Purchase	294	10.65
Purchase	307	10.65
Purchase	144	10.55
Purchase	160	10.55
Purchase	342	10.55
Purchase	327	10.55
Purchase	154	10.66
Purchase	340	10.56
Sale	1	10.57
Sale	1	10.57
Sale	1	10.57
Sale	18	10.57
Sale	1	10.57
Sale	316	10.57
Sale	264	10.6
Sale	1	10.57
Sale	200	10.57
Sale	1	10.57
Sale	1	10.57
Sale	1,498	10.56
Sale	28	10.56
Sale	114	10.56
Sale	981	10.56
Sale	441	10.65
Sale	435	10.57
Sale	42	10.57
Sale	1,040	10.57
Sale	349	10.57
Sale	135	10.56
Sale	13	10.58
Sale	1,664	10.58
Sale	1,360	10.58
Sale	1,967	10.58
Sale	361	10.58
Sale	291	10.56
Sale	14	10.58
Sale	13	10.58
Sale	501	10.6
Sale	114	10.66
Sale	381	10.65
Sale	452	10.65
Sale	200	10.56
Sale	4,071	10.56
Sale	185	10.56
Sale	200	10.66
Sale	1,000	10.65
Sale	1,000	10.56
Sale	1	10.66
Sale	200	10.65
Sale	800	10.65
Sale	1,000	10.6
Sale	385	10.65
Sale	1	10.66
Sale	200	10.66
Sale	2	10.66
Sale	2	10.66
Sale	381	10.56
Sale	995	10.6
Sale	404	10.66
Sale	1	10.57
Sale	1	10.57
Total Purchases	700,132
Total Sales	24,028

Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit GBP (Note 5)
CFD	Closing Long	194,541	10.58
CFD	Closing Long	5,926	10.58

(b)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(c)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements, or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any

relevant securities to which any derivative referred to on this form is referenced. If none, this

should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            No

Date of disclosure	02/06/2021
Contact name	Société Générale - Disclosure team
Telephone number	+33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEUPUUAQUPGUAP